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Summary
QUESTION UNDER STUDY: What are the trends in
avoidable cancer mortality in Switzerland and neighbour-
ing countries?
METHODS: Mortality data and population estimates
1996–2010 were obtained from the Swiss Federal Statist-
ical Office for Switzerland and the World Health Organ-
ization Mortality Database (http://www.who.int/healthinfo/
mortality_data/en/) for Austria, Germany, France and Italy.
Age standardised mortality rates (ASMRs, European stand-
ard) per 100 000 person-years were calculated for the pop-
ulation <75 years old by sex for the following groups of
cancer deaths: (1) avoidable through primary prevention;
(2) avoidable through early detection and treatment; (3)
avoidable through improved treatment and medical care;
and (4) remaining cancer deaths. To assess time trends
in ASMRs, estimated annual percentage changes (EAPCs)
with 95% confidence intervals (95% CIs) were calculated.
RESULTS: In Switzerland and neighbouring countries can-
cer mortality in persons <75 years old continuously de-
creased 1996–2010. Avoidable cancer mortality decreased
in all groups of avoidable cancer deaths in both sexes,
with one exception. ASMRs for causes avoidable through
primary prevention increased in females in all countries (in
Switzerland from 16.2 to 20.3 per 100 000 person years,
EAPC 2.0 [95% CI 1.4 to 2.6]). Compared with its neigh-
bouring countries, Switzerland showed the lowest rates for
all groups of avoidable cancer mortality in males
2008–2010.
CONCLUSION: Overall avoidable cancer mortality de-
creased, indicating achievements in cancer care and related
health policies. However, increasing trends in avoidable
cancer mortality through primary prevention for females
suggest there is a need in Switzerland and its European
neighbouring countries to improve primary prevention.
Key words: avoidable cancer mortality; cancer mortality;
Switzerland; Europe
Introduction
Mortality data and indicators (e.g. cause-specific mortality,
years of potential life lost) are widely used to assess the
health of populations and the quality of medical care within
a society. They are also one of the oldest forms of public
health information available to health authorities. Rutstein
and colleagues initially developed the concept of avoidable
mortality in 1976 [1]. They published a list of conditions
from which “disease, disability or death” should not occur
if appropriate care is provided. The concept of avoidable
mortality is based on the selection of causes of death con-
sidered to be amenable to medical care and/or health
policies. It is used as an indicator of the effectiveness of
the available healthcare services within a society. For inclu-
sion, not every single death caused by a condition is con-
sidered “avoidable”. Rather, it is essential that health ser-
vices and/or health policies can contribute substantially to
minimise mortality caused by the selected conditions. The
first population-based study using this concept was carried
out by Charlton et al. in 1983 to study regional variations
in avoidable mortality in England and Wales [2]. Subse-
quently, the concept was widely used by various research-
ers to investigate time trends and/or geographical disparit-
ies within or between regions, countries or social groups [3,
4].
Cancer remains one of the leading causes of mortality in
the developed world. In Switzerland, approximately 26%
of all deaths are caused by cancer [5]. Age is a primary
risk factor for cancer mortality, 67% of cancer deaths in
Switzerland occur in persons 65 years and older [6]. With
increasing longevity (i.e. average life expectancy 79.8
years in Swiss men and 84.4 years in Swiss women) cancer
prevalence is expected to increase [7]. A Swiss study based
on data from four Swiss cancer registries covering 7 out of
26 Swiss cantons estimated an increase in cancer prevalen-
ce from 289 797 cases in 2010 to 372 000 in 2020 [8]. De-
mand on the healthcare systems providing cancer care and
cancer-related healthcare costs are projected to rise accord-
ingly.
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 1 of 8
Measuring time trends in cancer morbidity and mortality
is an important tool for cancer control focused on address-
ing the public health needs within a country. Societies need
to monitor changes in populations at risk and evaluate out-
comes as well as the effectiveness of their healthcare sys-
tems serving those populations. Given the public health im-
portance of cancer in developed countries this study aimed
to examine avoidable cancer mortality in Switzerland and
neighbouring European countries. International comparis-
ons of avoidable cancer mortality highlight country-specif-
ic achievements as well as opportunities for improvement
in cancer care and/or health policies for cancer.
Methods
Data sources
Mortality data and mid-year population estimates for
Switzerland were provided by the Swiss Federal Statistical
Office (SFSO) covering the time period 1996 to 2010. Cor-
responding data for Austria, France, Germany and Italy
were obtained from the World Health organization (WHO)
Mortality Database (http://www.who.int/healthinfo/mortal-
ity_data/en/) providing mortality and population data com-
piled by the national health authorities [9]. Depending on
country and year, the underlying cause of death information
was coded according to the 9th (ICD-9) or 10th (ICD-10)
version of the International Classification of Diseases
(table 1). For Italy, no mortality data were available for
2004 and 2005. For France, population data were missing
for 2010.
Definition of avoidable cancer mortality
The selection of causes of death considered as avoidable
was based on the compilation of Simonato et al. [10]. For
this study, the original Simonato et al. list was restric-
ted to deaths caused by cancer. The list of Simonato et
al. is based on the original list of Rutstein et al. [1]. Si-
monato et al. undertook a further differentiation of avoid-
able causes of death and classified cancer deaths as: (1)
avoidable through primary prevention through exposure re-
duction (e.g. smoking and alcohol consumption); (2) avoid-
able through early detection and treatment (secondary pre-
vention); (3) avoidable through improved treatment and
medical care (tertiary prevention); and (4) remaining can-
cer deaths. The adaptions of Simonato et al. enabled the
distinct investigation of avoidable mortality by intervention
level followed by various researchers [11–13]. Because of
the rising evidence of mortality benefits of screening for
colorectal cancer, we included deaths caused by colorectal
cancer as avoidable through secondary prevention [14–18].
Specificity of cause of death and the extent of “avoidabil-
ity” decreases with age. Thus we restricted cancer deaths to
those occurring in persons less than 75 years old as sugges-
ted by Nolte and McKee [4]. We classified all cancer deaths
according to the categories presented in table 2.
Analytic methods
Annual and 3-year age-standardised mortality rates
(ASMRs, European standard) per 100 000 person-years
(PY) and corresponding 95% confidence intervals (95%
CIs) were calculated for the population aged less than 75
years by country, sex and group of avoidable cancer death
[19]. To analyse time trends in ASMRs, estimated annual
percentage changes (EAPC) were calculated using the nat-
ural log of ASMRs as target variable and the year of death
as predictor.
Results
ASMRs for avoidable cancer mortality and the remaining
cancer deaths by sex and country are presented in figure 1.
The corresponding EAPCs are listed in table 3. Cause-spe-
cific ASMRs and corresponding EAPCs for avoidable can-
cer mortality in Switzerland are listed in table 4.
Levels of avoidable cancer mortality in Switzerland
and neighbouring countries
Overall, cancer mortality in persons younger than 75 years
decreased continuously between 1996 and 2010 in all
countries under investigation. Comparing the time-periods
1996–1998 and 2008–2010, avoidable cancer mortality de-
creased by all groups of avoidable cancer mortality and
sex, with one exception. ASMRs for causes avoidable
Figure 1
Time trends in avoidable cancer mortality and remaining cancer
deaths (age-standardised mortality rate [ASMR], European
standard) by country and sex, time period 1996–2010.
Note: For Italy, data are lacking for 2004 and 2005. For France,
data are lacking for 2010.
Table 1: Cause of death coding (ICD-version) by country and time period.
Country ICD-9 ICD-10
Austria 1996–2001 2002–2010
France* 1996–1999 2000–2009
Germany 1996–1997 1998–2010
Italy† 1996–2002 2003, 2006–2009
Switzerland – 1996–2010
ICD = International Classification of Diseases 9th or 10th version
* For France, data are lacking for 2010.
† For Italy, data are lacking for 2004 and 2005.
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through primary prevention increased in females in all
countries reported. The highest increase was observed in
females in France with an EAPC of 3.3 (95% CI 3.0 to
3.7). Switzerland had the lowest rates of avoidable cancer
mortality for causes avoidable through primary prevention
in males (64.3 per 100 000 PY in 1996–1998, 50.4 per
100 000 PY in 2008–2010). Corresponding figures for fe-
males, (16.2 per 100 000 PY in 1996–1998 and 20.3 per
100 000 PY in 2008–2010), were midrange compared with
neighbouring countries. For causes avoidable through early
detection and treatment, Switzerland had comparably low
ASMRs (males 13.0 per 100 000 PY, females 29.2 per
100 000 PY, 2008–2010) with an EAPC of –1.7 (95% CI
–2.4 to –1.1) in males and –1.7 (95% CI –2.1 to –1.4) in
females. Compared with neighbouring European countries,
mortality for causes avoidable through improved treatment
and care were lowest in Switzerland. In 2008‒2010, 4.1
deaths per 100 000 PY (EAPC –1.9, 95% CI –3.0 to –0.7)
for causes avoidable through improved treatment and care
were observed in males and 2.4 per 100 000 PY (EAPC
–1.9, 95% CI –3.6 to −0.3) in females.
Cause-specific avoidable cancer mortality in
Switzerland
Shifts in cancer mortality avoidable through primary pre-
vention have been mainly driven by increasing numbers of
deaths caused by cancer of the lung, bronchus and trachea.
In males, mortality from cancer of the lung, bronchus and
trachea decreased from 40.7 per 100 000 PY in 1996–1998
to 29.7 in 2008‒2010 (EAPC –2.6, 95% CI –3.0 to –2.1).
For the same time periods, an increase from 10.8 to 14.8
per 100 000 PY was observed in females with an EAPC
of 2.7 (95% CI 2.1 to 3.3). Cancer-specific mortality rates
with cancers avoidable through early detection and treat-
ment decreased in both sexes. In females, EAPCs varied
between –0.6 (95 % CI –1.9 to 0.7) for skin cancer and
–3.6 (95% CI –5.0 to –0.5) for cervical cancer. In males,
EAPCs ranged from –1.0 (95% CI –2.6 to 0.6) for skin can-
cer to –1.9 (95% CI –2.6 to –1.2) for colorectal cancer. In
the group of cancer mortality avoidable through improved
treatment and medical care, significant changes in mortal-
ity rates were observed only for leukaemia (EAPC –1.7,
95% CI –2.9 to –0.5 males; ‒2.1, 95% CI ‒3.7 to –0.4 fe-
males). The highest, albeit not significant, decrease was
found for testicular cancer (EAPC ‒4.7, 95% CI –1.0 to
0.6). The most common cause of avoidable cancer mortal-
ity in females during 2008‒2010 was breast cancer, with
an ASMR of 18.1 per 100 000 PY, followed by cancer of
the lung, bronchus and trachea (14.8 per 100 000 PY) and
colorectal cancer (6.5 per 100 000 PY). In men, cancer
of the lung, bronchus and trachea (29.7 per 100 000 PY),
cancer of the upper airways and digestive tract (10.7 per
100 000 PY) and colorectal cancer (10.6 per 100 000 PY)
were the leading causes of avoidable cancer mortality.
Discussion
In this paper, mortality and population data from the SFSO
and the WHO mortality database were used to describe
levels and trends in avoidable cancer mortality 1996–2010
for Switzerland and its neighbouring European countries.
We split avoidable cancer mortality into three literature-
based groups of intervention levels as proxy measures for
the effectiveness of healthcare and health policies in the
countries under investigation [10, 12].
Cancer mortality avoidable through primary
prevention
In Switzerland, the group of cancer deaths avoidable
through primary prevention represented almost half of all
cancer deaths in males and nearly one-quarter in females.
Despite an overall decreasing trend in avoidable cancer
mortality in both sexes, cancer mortality avoidable through
primary prevention increased substantially in the female
population consistently across all countries.
The majority of cancer deaths avoidable through primary
prevention in Switzerland were from cancers (lung, bron-
chus, trachea, upper airways, digestive tract) highly related
to tobacco exposure. In 2004, the WHO estimated that
approximately one-quarter of Western European cancer
deaths, (Austria 23%, France 27%, Germany 25%, Italy
27%, Switzerland 23%) were attributable to tobacco expos-
ure [20]. Crude cancer death rates in the male population
aged ≥30 years were highest in France (213 per 100 000
PY) and lowest in Switzerland (122 per 100 000 PY). In fe-
Table 2: Categorisation of avoidable cancer mortality (adapted from Simonato et al. [10]).
Causes of death ICD-9 ICD-10
1. Causes avoidable through primary prevention
Cancer of upper airways and digestive tract 140‒150, 161 C00‒C15, C32
Liver cancer 1 550 C22
Cancer of lung, bronchus and trachea 162 C33, C34
Bladder cancer 188 C67
2. Causes avoidable through early detection and treatment
Skin cancer (melanoma and non-melanoma) 172, 173 C43, C44
Female breast cancer 174 C50
Cervical cancer 180 C53
Uterine cancer 179, 182 C54, C55
Colorectal cancer 153‒154 C18‒C21
3. Causes avoidable through improved treatment and medical care
Testicular cancer 186 C62
Hodgkin’s disease 201 C81
Leukaemia 204‒208 C91‒C95
ICD = International Classification of Diseases, 9th or 10th version
Original article Swiss Med Wkly. 2015;145:w14184
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 3 of 8
males, the highest rates were in Germany (39 per 100 000
PY) [20].
In Western Europe, tobacco consumption peaked through
the 1960s and 1970s with high proportions of male smokers
(50% and more). The 1980s and 1990s showed a downturn
in total tobacco consumption, driven by decreasing propor-
tions of male smokers [21, 22]. While smoking prevalen-
ce in males levelled off and/or dropped the proportions of
Table 3: Age-standardised mortality rates per 100 000 person-years (European standard) for time periods 1996‒1998 and 2008–2010 and estimated annual percentage
changes 1996–2010 by country, sex and group of avoidable cancer deaths.
Males* Females*
ASMR EAPC ASMR EAPC
Groups of avoidable cancer deaths and
remaining cancer deaths by country
1996‒1998 2008‒2010
95% confidence limits
1996‒1998 2008‒2010
95% confidence limits
Austria
Primary prevention 70.0 59.3 −1.4 (−1.7, −1.2) 16.7 21.3 1.9 (1.6, 2.3)
Early detection/treatment 23.7 16.2 −3.1 (−3.7, −2.6) 41.1 29.2 −2.8 (−3.2, −2.5)
Improved treatment/care 5.7 4.8 −0.8 (−1.9, 0.2) 3.6 2.6 −2.5 (−3.9, −1.1)
Remaining cancer deaths 60.1 49.3 −1.7 (−2.1, −1.3) 37.8 32.7 −1.3 (−1.7, −0.8)
France†
Primary prevention 100.8 80.0 −2.0 (−2.2, −1.8) 12.9 19.0 3.3 (3.0, 3.7)
Early detection/treatment 17.6 15.2 −1.4 (−1.6, −1.0) 38.2 32.6 −1.5 (−1.7, −1.2)
Improved treatment/care 5.4 5.0 −0.8 (−1.4, −0.2) 3.4 2.7 −2.1 (−2.4, −1.7)
Remaining cancer deaths 71.3 56.7 −2.1 (−2.4, −1.8) 33.7 28.8 −1.4 (−1.7, −1.2)
Germany
Primary prevention 75.8 59.6 −2.0 (−2.1, −1.9) 16.6 21.6 2.2 (2.0, 2.3)
Early detection/treatment 22.2 16.3 −2.6 (−2.8, −2.3) 43.6 32.4 −2.5 (−2.7, −2.3)
Improved treatment/care 5.9 4.6 −2.3 (−2.7, −1.8) 3.7 2.7 −2.6 (−2.9, −2.4)
Remaining cancer deaths 63.7 52.1 −1.7 (−2.0, −1.5) 41.1 33.4 −1.8 (−2.0, −1.6)
Italy‡
Primary prevention 85.6 60.3 −2.9 (−3.1, −2.7) 13.6 16.0 1.5 (1.1, 1.9)
Early detection/treatment 18.1 15.4 −1.3 (−1.4, −1.1) 37.9 31.1 −1.6 (−1.8, −1.4)
Improved treatment/care 6.3 5.2 −1.4 (−1.8, −1.0) 3.8 3.1 −1.6 (−2.0, −1.3)
Remaining cancer deaths 65.8 49.7 −2.4 (−2.6, −2.1) 38.8 32.5 −1.5 (−1.8, −1.3)
Switzerland
Primary prevention 64.3 50.4 −2.0 (−2.4, −1.7) 16.2 20.3 2.0 (1.4, 2.6)
Early detection/treatment 16.3 13.0 −1.7 (−2.4, −1.1) 35.9 29.2 −1.7 (−2.1, −1.4)
Improved treatment/care 4.9 4.1 −1.9 (−3.0, −0.7) 2.8 2.4 −1.9 (−3.6, −0.3)
Remaining cancer deaths 54.2 42.2 −2.2 (−2.6, −1.8) 33.8 27.1 −1.7 (−2.1, −1.2)
ASMR = age-standardised mortality rate; EAPC = estimated annual percentage change
* Population aged less than 75 years.
† No data available for 2010.
‡ No data available for 2004 and 2005.
Table 4: Swiss cancer-specific age-standardised mortality rates per 100 000 person-years (European standard) for time periods 1996–1998 and 2008–2010 with estimated
annual percentage changes 1996–2010 by sex and group of avoidable cancer deaths.
Males* Females*
ASMR EAPC ASMR EAPC
Groups of avoidable cancer deaths by
cancer site
1996–1998 2008–2010
95% confidence limits
1996–1998 2008–2010
95% confidence limits
1. Primary prevention
Cancer of upper airways and digestive tract 13.5 10.7 −2.0 (−2.6, −1.4) 2.5 2.6 0.3 (−1.2, −1.8)
Liver cancer 6.4 7.0 0.7 (0.1, 1.5) 1.7 1.8 1.2 (−0.5, 2.8)
Cancer of lung, bronchus and trachea 40.7 29.7 −2.6 (−3.0, −2.1) 10.8 14.8 2.7 (2.1, 3.3)
Bladder cancer 3.7 3.0 −2.2 (−3.6, −0.8) 1.2 1.0 −0.7 (−2.7, 1.3)
2. Early detection/treatment
Skin cancer 3.0 2.4 −1.0 (−2.6, 0.6) 1.7 1.6 −0.6 (−1.9, 0.7)
Female breast cancer – – – – 22.5 18.1 −1.8 (−2.4, −1.3)
Cervical cancer – – – – 1.8 1.1 −3.6 (−5.0, −2.1)
Uterine cancer – – – – 2.2 2.0 −1.3 (−2.3, −0.4)
Colorectal cancer 13.3 10.6 −1.9 (−2.6, −1, 2) 7.7 6.5 −1.5 (−2.3, −0.6)
3. Improved treatment/care
Testicular cancer 0.3 0.2 −4.7 (−1.0, 0.6) – – – –
Hodgkin’s disease 0.3 0.3 −0.7 (−5.0, 3.5) 0.2 0.3 −0.2 (−5.5, 5.0)
Leukaemia 4.2 3.5 −1.7 (−2.9, −0.5) 2.6 2.1 −2.1 (−3.7, −0.4)
ASMR = age-standardised mortality rate; EAPC = estimated annual percentage change
* Population aged less than 75 years.
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female smokers increased [23]. Despite this fact, the over-
all smoking prevalence in Switzerland and its neighbouring
European countries was consistently higher in males than
females [21]. The Swiss health survey found that smoking
prevalence in males was higher in 1992 than 2012 but
stable in females [24]. In 2012, nearly one-third of Swiss
males and one-quarter of Swiss females were self-reported
current smokers [24]. The prevalence of female smokers
decreased slightly in Germany (since 2000) and Italy (since
1990) after increasing for decades [25, 26]. For Austrian
and French females, there is evidence of a continuous rise
in smoking prevalence until at least 2007 [22, 27]. Increas-
ing trends in female smoking prevalence, reported in the
second half of the last century, are reflected in our res-
ults, which show a substantial rise in tobacco-related can-
cer deaths. Looking at more recent data, the Organisation
for Economic Co-operation and Development (OECD) re-
ported substantial declines in female smoking proportions
between 2000 and 2011 for most of its member states (with
the exception of Czech Republic, France and Italy where
no or modest declines were observed) [28]. However, given
the long latency period for tobacco-related cancers, future
increases in female cancer mortality avoidable through
primary prevention are foreseen.
Cause-specific analyses of avoidable cancer deaths in
Switzerland revealed an increase in liver cancer mortality
in both sexes. Results were not significant in females, ab-
solute changes in rates were comparably low, and the ob-
served rise contributed little to the overall trend of cancer
deaths avoidable through primary prevention. Nonetheless,
the finding should stimulate public health awareness and
emphasises the need for further investigation.
Cancer mortality avoidable through early detection
and treatment
In all countries under investigation, cancer mortality avoid-
able through early detection and treatment decreased in
both sexes. Women showed substantially lower ASMRs for
overall cancer mortality than men, but higher rates for can-
cer mortality avoidable through early detection and treat-
ment. This result can be explained by taking a closer look at
the distinct conditions classified as avoidable through early
detection and treatment and the individual rates of these
conditions. Three out of five conditions classified as avoid-
able through early detection and treatment are specific for
females, such as female breast cancer, the leading cause of
cancer mortality in women. In 2008–2010, Switzerland and
its neighbouring European countries had comparable levels
of female cancer mortality classified as avoidable through
early detection and treatment. In the same period, there was
slightly more variation in cancer mortality rate avoidable
through early detection and treatment in males, with the
lowest levels in Switzerland.
In 2003, the council of the European Union (EU) published
EU screening guidelines and called upon the member states
to implement effective screening programmes for breast,
colorectal and cervical cancers. In 2007, the EU Commis-
sion reported on the status of screening implementation
[29]. Of the European countries neighbouring Switzerland,
only Italy had started or planned the introduction of nation-
wide, population-based screening programmes for all three
recommended cancer sites. In Switzerland, healthcare is or-
ganised at the cantonal level, leading to substantial regional
differences in the provision of primary preventive services
[30]. Up to the end of the study period, organised can-
cer screening programmes had been implemented only for
breast cancer and mainly in the Western part of the coun-
try [31–33]. Organised screening programmes are more
likely to reduce mortality and achieve high coverage in
the target population compared with opportunistic screen-
ing [34]. Nonetheless, organised programmes with inad-
equate resources or insufficient infrastructure may perform
more poorly than opportunistic screening options, emphas-
ising the need for programme evaluation [34]. Our findings
of decreased cancer mortality avoidable by early detection
and treatment suggest improvements in the quality of
screening activities and/or population coverage in the
countries studied herein.
Cancer mortality avoidable through improved
treatment and medical care
Cancer mortality avoidable through improved treatment
and medical care declined in both sexes and all countries
under investigation. Compared with its neighbouring coun-
tries, Switzerland had slightly lower ASMRs for causes
avoidable through improved treatment and medical care.
However, cancer mortality avoidable through improved
treatment and medical care represented only 3–4% of all
cancer deaths in both sexes. Therefore, these decreases
contributed minimally to the overall decrease of avoidable
cancer mortality, despite EAPCs comparable with cancer
mortality avoidable through early detection and treatment.
For most cancer sites, there is little basis suggesting strik-
ing mortality benefits at the population level due to ad-
vances in cancer treatments [35, 36]. There are, however,
a few cancer types for which substantial improvements in
treatments have been achieved over the last decades. For
these cancers (e.g. testicular, Hodgkin’s) a reduction in
mortality has been observed independent of changes in in-
cidence [35]. Testicular cancer has become a curable dis-
ease primarily owing to the development of more effective
chemotherapy regimens [35, 37]. Although advanced treat-
ment for testicular cancer has been available since 1970,
declines in mortality have been greater in the USA than
the EU and substantial mortality differences have been
observed between European countries [38–40]. For
Hodgkin’s disease, effective treatment has been available
for several decades [41]. Improvements in Hodgkin’s treat-
ments have been driven by enhancements in diagnostic
methods, technical advancements in radiotherapy and the
introduction of new chemotherapy regimens [41, 42]. Fur-
thermore, there is evidence that high cure rates for
Hodgkin’s disease can be achieved even for advanced stage
disease if treated appropriately [42]. Consequently, mor-
tality from Hodgkin’s disease has dropped substantially
in Western European countries since the early 1970s.
However, differences between regions and countries sug-
gest there is room for further improvements in the im-
plementation of available therapies [35, 43–45]. For leuk-
aemia, favourable mortality trends have been observed in
several European countries since 1970, initiated by intro-
duction of multidrug chemotherapy and/or improved radio-
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therapy [46]. However, leukaemia includes a heterogen-
eous group of diseases with varying treatment options and
prognoses [35]. Substantial treatment-related mortality re-
ductions were found mainly in children, and young and
middle-aged adults [35, 46]. We observed moderate de-
creases in EAPCs for cancer deaths avoidable through im-
proved treatment and medical care in all countries under
investigation. Our study period (1996‒2010) was relatively
late compared with the availability of the advanced treat-
ment options mentioned above. The effect of the introduc-
tion of these types of treatment improvements were not
seen in our results most likely because they had already be-
come the accepted clinical standard prior to the study peri-
od.
Strengths and limitations
The study is the first population-based investigation in
Switzerland and neighbouring European countries to exam-
ine the effectiveness of medical care by intervention level
(primary, secondary and tertiary prevention) using avoid-
able cancer mortality as quality indicator. The concept of
avoidable mortality has been widely used internationally to
estimate the effectiveness of healthcare using official mor-
tality data readily available for almost all developed coun-
tries.
There are some limitations to this research study worth
mentioning. Particularly, cross-national differences and/or
changes over time in death certification and coding prac-
tices may have influenced the results. For example, France
changed in 2000 from ICD-9 to ICD-10 for cause-of-death
coding and replaced manual coding of deaths with a new
automated system. Meslé and Vallin investigated the im-
pact of these changes and detected discontinuities even
at the crude levels (i.e., ICD primary categories) [47].
However, we did not detect any suspicious breaks in time
trends for the cancer groups under investigation. Despite
this fact, effects from coding-related differences between
countries and across time periods cannot be completely
ruled out.
We investigated a relatively short time period of 15 years
using 1996 as starting point. In Switzerland, the definition
of the underlying cause of death deviated from internation-
al standards up to 1995. In brief, cancer was given prior-
ity as underlying cause of death if the word “tumour” was
mentioned anywhere on a death certificate. This resulted in
higher cancer mortality rates prior to 1995 [48, 49]. As a
result, the investigation of long-term trends (i.e. covering
several decades) was not feasible within this study.
Further, every list of causes of death considered as avoid-
able is – at least to some extent – dependent on the view
of the respective researcher(s) who developed it. Since the
introduction of the concept in 1976, competing approaches
have led to varying lists of single conditions and groups
of conditions defined as avoidable. In this study, we used
an adapted version of the list of Simonato et al., because it
was intended to measure the effectiveness of cancer treat-
ment as well as the impact of primary, secondary and ter-
tiary prevention policies related to cancer [10]. However,
there are certain overlaps between the mortality categor-
ies assigned to each condition. For example, Tobias and
Jackson [13] assumed that in New Zealand (1981–1997)
15% of avoidable female breast cancer deaths are avoid-
able through primary prevention, 35% through secondary
prevention and 50% through tertiary prevention.
Another point of criticism regarding the concept of avoid-
able mortality is the one-dimensional focus on mortality as
a measure of the quality of healthcare [4]. It is widely ac-
cepted that to accurately measure the quality of medical
care it should be assessed in three dimensions: (1) struc-
tures, (2) processes and (3) outcomes [50–52]. Although
a very important one, mortality is just one potential out-
come of interest. Hence, interpretation of these results is
limited since individual indicators, like mortality, cannot
alone capture the effectiveness of healthcare services.
Conclusion
Overall, these results suggest comparable trends in avoid-
able cancer mortality for Switzerland and its neighbouring
European countries. Avoidable cancer mortality has de-
creased in both sexes and all countries reported. However,
cancer mortality avoidable through primary prevention in-
creased substantially in females in all countries under in-
vestigation, indicating that there is a need to increase
gender-specific primary prevention (e.g. anti-smoking
campaigns targeting females). Despite this trend, cancer
deaths avoidable through primary prevention were much
less common in females than in males, indicating to sup-
port primary prevention for both sexes in the near future.
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Figures (large format)
Figure 1
Time trends in avoidable cancer mortality and remaining cancer deaths (age-standardised mortality rate [ASMR], European standard) by country
and sex, time period 1996–2010.
Note: For Italy, data are lacking for 2004 and 2005. For France, data are lacking for 2010.
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